Developer docs
API playgroundTry for free, no card

Search company profiles

Hanmi Pharmaceutical

Full company profile

uuid0002g79

Namestring
Hanmi Pharmaceutical
Legal namestring
Hanmi Pharm. Co., Ltd.
Websiteurl
hanmipharm.com
Company typeenum
Public
Founded yearint
1973
Descriptiontext

Hanmi Pharmaceutical is a South Korea-headquartered pharmaceutical company founded in 1973 and publicly listed on the KOSPI exchange since 1988, operating as the core pharmaceutical subsidiary of Hanmi Science. It ranks among the top five Korean pharmaceutical companies by revenue, employs 5,001-10,000 people, and is notable for spending more than 10% of annual revenue on R&D. The company develops, manufactures, and commercializes drugs across three therapeutic franchises: obesity/metabolism, oncology, and rare diseases, alongside incremental modifications of existing drugs through novel formulation work. International operations span Seoul headquarters, an R&D Center in Dongtan, manufacturing at Paltan (6+ billion tablets/year) and Pyeongtaek Bioplant (bioreactors up to 12,500L), plus subsidiaries in Beijing (China, 20%+ CAGR), Tokyo, and London.

The company's technology foundation rests on proprietary platforms. LAPSCOVERY is a long-acting protein/peptide discovery platform enabling once-weekly or monthly dosing through Fc fusion with flexible linkers, validated by FDA-approved Rolontis/Rolvedon (eflapegrastim). PENTAMBODY is a bispecific antibody platform with natural IgG-like architecture for immuno-oncology. HARP is an in-house AI-driven research platform that contributed to the discovery of obesity candidate HM17321, with related research in protein language models (HARP-pSAR) and proteomics-based phenotype prediction. Manufacturing spans biopharmaceuticals (microbial culture, biochemical conjugation), fine chemicals (APIs, peptides, PEG, NTP, mRNA cap analogs), and chemical drugs, supported by FDA- and MFDS-approved facilities.

Hanmi operates three primary revenue streams. Licensing-out agreements with global pharmaceutical companies (Eli Lilly, Sanofi, Janssen, Boehringer Ingelheim, MSD, Genentech) generate upfront payments, development and regulatory milestones, and royalties; the 2026 sonefpeglutide deal with Eli Lilly is valued at up to $1.26 billion. Direct pharmaceutical product sales are concentrated in Korea, where Hanmi has held the #1 outpatient prescription ranking for four consecutive years with brands such as Amosartan and Amodipin. CDMO services across Bio, Fine Chemical, and Chemical divisions provide contract manufacturing to global pharma clients. International expansion occurs through Beijing Hanmi (China), regional distribution partners (Organon for Malaysia and Philippines, Laboratorios Sanfer for Mexico), and licensing deals that grant partners global rights while Hanmi retains Korean commercialization rights.

Short descriptiontext

Hanmi Pharmaceutical is a South Korean top-5 pharmaceutical company developing innovative obesity, oncology, and rare disease drugs through proprietary platforms (LAPSCOVERY, PENTAMBODY, HARP AI). Revenue derives from global licensing deals, Korean prescription drug sales, and CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative pharmaceutical products, long-acting biologics, obesity drug development, contract pharmaceutical manufacturing, drug licensing partnerships
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing-out Deals
TypeLicensing Royalties
Description

Hanmi licenses its proprietary drug candidates to global pharmaceutical companies for upfront payments, milestone payments, and royalties. Examples include $1.26B deal with Eli Lilly for sonefpeglutide ($75M upfront + $1.185B milestones), and deals with Sanofi, Janssen, Boehringer Ingelheim, MSD, and Genentech. Revenue recognition occurs at deal signing, milestone achievements, and ongoing royalties post-launch.

hanmipharm.com
2CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing services across three divisions: Bio (biopharmaceuticals with microbial culture), Fine Chemical (APIs, peptides, PEG, NTP, mRNA cap analog), and Chemical (synthetic medicines with 6+ billion tablets annual capacity). Services include development, GMP manufacturing, and regulatory support.

hanmipharm.com
3Pharmaceutical Product Sales
TypeOne Time License
Description

Direct sales of pharmaceutical products in Korea and through international subsidiaries. Products include Amosartan (antihypertensive), Amodipin, and other incrementally modified drugs. Korean market leadership with #1 outpatient prescription ranking for multiple years.

hanmipharm.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Hanmi Pharmaceutical develops, manufactures, and commercializes innovative pharmaceutical products across obesity/metabolism, oncology, and rare diseases using proprietary platform technologies (LAPSCOVERY, PENTAMBODY, HARP AI, IMD/New Formulation). The company sells branded drugs directly in Korea and China, licenses out proprietary drug candidates to global pharma partners (Eli Lilly, Sanofi, Janssen, MSD, Genentech), and provides CDMO services across Bio, Fine Chemical, and Chemical divisions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 28.7% mean weight loss achieved by Eli Lilly's retatrutide setting benchmark for obesity drugs (source for market context)
+2 more records
Product and service9 records
1Amosartan
CategoryCardiovascular Pharmaceuticals
Description

World's first fixed-dose combination (FDC) of Amlodipine and Losartan for hypertension treatment, sold in Korea as a major breakthrough product in the cardiovascular therapeutic area.

2Amodipin
CategoryCardiovascular Pharmaceuticals
Description

Korea's first incrementally modified drug (IMD) — a new salt form of amlodipine for hypertension treatment, patented in 2004 and commercially launched.

3Rolontis (eflapegrastim)
CategoryOncology Biologics
Description

FDA-approved long-acting G-CSF biologic (eflapegrastim) developed using LAPSCOVERY platform for treatment of chemotherapy-induced neutropenia. Included in NCCN Treatment Guidelines for 32 cancer centers in the US.

4Efpeglenatide (GLP-1 obesity and diabetes drug)
CategoryObesity/Metabolism Pharmaceuticals
Description

Hanmi's proprietary GLP-1 receptor agonist for obesity and diabetes treatment. Korea's first independently developed obesity therapy, demonstrating best-in-class protective efficacy for cardiovascular/renal disease among GLP-1s. Licensed to Laboratorios Sanfer for exclusive distribution in Mexico.

5Sonefpeglutide (LAPSGLP-2 analog)
CategoryRare Disease Pharmaceuticals
Description

Long-acting GLP-2 analog developed using LAPSCOVERY platform for treatment of short bowel syndrome, currently in global Phase 2 trial. Licensed to Eli Lilly for $1.26 billion in upfront and milestones.

6HM500197 (LA-MSTN)
CategoryObesity/Metabolism Pharmaceuticals
Description

World's first peptide-based long-acting myostatin (LA-MSTN) inhibitor for obesity, designed to selectively inhibit myostatin and increase skeletal muscle-focused lean mass while minimizing off-target activity. Can be developed as combination therapy with GLP-1-based treatments.

7Efocipegtrutide (LAPSTriple Agonist)
CategoryObesity/Metabolism Pharmaceuticals
Description

Long-acting triple agonist (GLP-1/GIP/Glucagon) for treatment of obesity and MASH (non-alcoholic steatohepatitis), granted FDA Fast Track designation.

8Efeglucagon / Efpegerglucagon (HM15136)
CategoryRare Disease Pharmaceuticals
Description

Long-acting glucagon analog being developed as the world's first once-weekly formulation for congenital hyperinsulinism, a rare disease with no current FDA-approved treatment. Received FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.

9CDMO Services
CategoryContract Manufacturing Services
Description

Contract Development and Manufacturing Organization services across three divisions: Bio (biopharmaceuticals with microbial culture and biochemical reaction processes), Fine Chemical (APIs, peptides, PEG, NTP, mRNA cap analog), and Chemical (synthetic medicines with 6+ billion tablets annual capacity). Services include development, GMP manufacturing, and regulatory support.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Licensing agreement worth up to $1.26 billion for sonefpeglutide (LAPSGLP-2 analog) for short bowel syndrome. Hanmi receives $75 million upfront and up to $1.185 billion in clinical development, regulatory, and commercialization milestone payments, plus royalties. Lilly gains exclusive worldwide rights outside Korea. Hanmi continues global Phase 2 trial while Lilly explores additional clinical trials.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-21
Description

Supply agreement to export three combination medications for cardiovascular and respiratory health to Malaysia and Philippines. Hanmi supplies finished products while Organon handles marketing, distribution, and sales in local markets. Partnership targets rapidly growing Southeast Asian pharmaceutical market driven by increasing chronic disease prevalence.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

Exclusive distribution agreement for efpeglenatide GLP-1 obesity drug and Dapalon-lineup diabetes treatments in Mexico. Hanmi supplies finished formulations while Sanfer handles regulatory approvals, marketing, and sales. Mexico has high obesity prevalence (36.86%) and diabetes prevalence (16.4%), making it strategically valuable market.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Hanmi acquiring all outstanding shares of Aptose at C$2.41 per share in cash (28% premium over 30-day VWAP). Hanmi already owns nearly 20% of Aptose and has provided debt support of over US$30 million during past 18 months. Deal supports continued development of tuspetinib-based therapy for AML. First direct entry into North America for Hanmi.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Joint development of bsAb ADC (bispecific antibody-drug conjugate) for cancer using PENTAMBODY platform.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Licensing-out of Luminate (risuteganib) for dry AMD to Greater China region.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Licensing agreement for tuspetinib (HM43239, myeloid kinome inhibitor) for AML worldwide. Hanmi also providing financing support and pursuing acquisition of Aptose.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

Licensing-out of HA injection (sodium hyaluronate) for joint articular use in US.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Licensing agreement for efinopegdutide (HM12525A, GLP-1/Glucagon) for MASH worldwide excluding Korea.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Enzyme replacement therapy partnership for HM15421/GC1134A (long-acting ERT) for lysosomal storage disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-01-01
Description

PENTAMBODY-based bispecific antibody BH2950/IBI315 (PD-1/HER2 antagonist) for cancer development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2016-01-01
Description

Licensing agreement for belvarafenib (HM95573, pan-RAFi) for solid tumor treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Multiple licensing agreements including Amosartan Q for CIS markets and joint development of fixed-dose combinations like Robelito (ARB-statin combination), Korea's first such combination drug.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Licensing agreement for HM12525A (GLP-1/Glucagon dual agonist) for diabetes and obesity worldwide excluding Korea, China, and Greater China.

15Boehringer Ingelheim
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Licensing partnership for autoimmune disease therapeutics.

hanmipharm.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2015-01-01
Description

Licensing agreement for olmutinib (HM61713, EGFRi) for solid tumor in China.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Licensing agreement for poseltinib (HM71224, BTKi) for autoimmune diseases worldwide excluding Korea and Greater China.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Joint development of dual antibody ADC anticancer drug using PENTAMBODY ConjuAll platform technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Licensing agreement for poziotinib (HM781-36B, pan-HER inhibitor) for solid tumors worldwide excluding Korea and China. Strategic investment of KRW 24 billion in Spectrum.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2012-01-01
Description

Licensing agreement for Rolvedon (eflapegrastim, HM10460A, G-CSF) for neutropenia worldwide excluding Korea, China, and Japan.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Novo Nordisk is the global GLP-1 obesity/diabetes market leader with semaglutide (Ozempic/Wegovy). Directly comparable as the dominant obesity/metabolism incumbent against whose commercial franchise Hanmi's efpeglenatide and other pipeline assets must compete for market share.

TypeDirect peer
Description

Celltrion is a leading Korean biopharmaceutical company specializing in biosimilars and novel biologics, with global licensing partnerships. Directly comparable to Hanmi's biologics manufacturing capabilities (Pyeongtaek Bioplant) and biosimilar/innovative biologics pipeline strategy.

TypeDirect peer
Description

Dong-A Pharmaceutical is a Korean pharmaceutical company of similar size with branded generics, specialty therapeutics, and incremental drug modification focus. Comparable to Hanmi's domestic prescription franchise, R&D pipeline, and Korean market leadership ambitions.

TypeDirect peer
Description

Yuhan Corporation is one of the largest Korean pharmaceutical companies by revenue, with a similar branded-pharma business model and growing CDMO operations. It is directly comparable to Hanmi in scale, therapeutic focus areas (respiratory, oncology, chronic disease), and Korean-market leadership profile.

TypeBroad incumbent
Description

Eli Lilly is the global leader in obesity therapeutics with retatrutide and tirzepatide franchises, and is also Hanmi's licensing partner for sonefpeglutide. Comparable as an obesity/metabolism market incumbent whose commercial scale sets the benchmark Hanmi's pipeline must compete against.

6Chong Kun Dang Pharmaceutical
TypeDirect peer
Description

Chong Kun Dang is a Korean pharmaceutical company with similar size, branded-generic portfolio, and incremental drug modification focus. Directly comparable to Hanmi's domestic Korean prescription business and IMD/new formulation technology platform.

TypeEmerging player
Description

Innovent Biologics is a Chinese innovative biopharmaceutical company that partnered with Hanmi on PENTAMBODY-based bispecific antibody BH2950/IBI315. Comparable as an emerging oncology biologics developer with similar bispecific antibody technology focus and licensing partnership patterns.

TypeDirect peer
Description

Daewoong Pharmaceutical is a Korean top-tier pharmaceutical company with direct overlap in incrementally modified drugs, GLP-1 development (envafolimab), and botulinum toxin franchises. Similar in size, business model, and pipeline focus to Hanmi's branded pharma business.

TypeDirect peer
Description

Samsung Biologics is a global CDMO and biosimilars developer operating large-scale mammalian cell culture manufacturing facilities. Comparable to Hanmi's CDMO business (Bio division) and global pharma contract manufacturing partnerships with Lilly, Roche, and other major companies.

10LG Chem Life Sciences
TypeDirect peer
Description

LG Chem's Life Sciences division is a Korean specialty pharmaceutical company focused on innovative drugs, vaccines, and CDMO services. Comparable to Hanmi in branded pharma operations, specialty therapeutics focus, and CDMO scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment12 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hanmi Pharmaceutical

Pharmaceutical Productshanmipharm.com

Hanmi Pharmaceutical is a South Korean top-5 pharmaceutical company developing innovative obesity, oncology, and rare disease drugs through proprietary platforms (LAPSCOVERY, PENTAMBODY, HARP AI). Revenue derives from global licensing deals, Korean prescription drug sales, and CDMO services.

What Hanmi Pharmaceutical does

Hanmi Pharmaceutical is a South Korea-headquartered pharmaceutical company founded in 1973 and publicly listed on the KOSPI exchange since 1988, operating as the core pharmaceutical subsidiary of Hanmi Science. It ranks among the top five Korean pharmaceutical companies by revenue, employs 5,001-10,000 people, and is notable for spending more than 10% of annual revenue on R&D. The company develops, manufactures, and commercializes drugs across three therapeutic franchises: obesity/metabolism, oncology, and rare diseases, alongside incremental modifications of existing drugs through novel formulation work. International operations span Seoul headquarters, an R&D Center in Dongtan, manufacturing at Paltan (6+ billion tablets/year) and Pyeongtaek Bioplant (bioreactors up to 12,500L), plus subsidiaries in Beijing (China, 20%+ CAGR), Tokyo, and London.

The company's technology foundation rests on proprietary platforms. LAPSCOVERY is a long-acting protein/peptide discovery platform enabling once-weekly or monthly dosing through Fc fusion with flexible linkers, validated by FDA-approved Rolontis/Rolvedon (eflapegrastim). PENTAMBODY is a bispecific antibody platform with natural IgG-like architecture for immuno-oncology. HARP is an in-house AI-driven research platform that contributed to the discovery of obesity candidate HM17321, with related research in protein language models (HARP-pSAR) and proteomics-based phenotype prediction. Manufacturing spans biopharmaceuticals (microbial culture, biochemical conjugation), fine chemicals (APIs, peptides, PEG, NTP, mRNA cap analogs), and chemical drugs, supported by FDA- and MFDS-approved facilities.

Hanmi operates three primary revenue streams. Licensing-out agreements with global pharmaceutical companies (Eli Lilly, Sanofi, Janssen, Boehringer Ingelheim, MSD, Genentech) generate upfront payments, development and regulatory milestones, and royalties; the 2026 sonefpeglutide deal with Eli Lilly is valued at up to $1.26 billion. Direct pharmaceutical product sales are concentrated in Korea, where Hanmi has held the #1 outpatient prescription ranking for four consecutive years with brands such as Amosartan and Amodipin. CDMO services across Bio, Fine Chemical, and Chemical divisions provide contract manufacturing to global pharma clients. International expansion occurs through Beijing Hanmi (China), regional distribution partners (Organon for Malaysia and Philippines, Laboratorios Sanfer for Mexico), and licensing deals that grant partners global rights while Hanmi retains Korean commercialization rights.

Hanmi Pharmaceutical firmographics

Firmographics
Name
Hanmi Pharmaceutical
Legal name
Hanmi Pharm. Co., Ltd.
Website
https://hanmipharm.com
Company type
Public
Founded year
1973
Operating status
Operating
Headcount range
51–100 employees
Short description
Hanmi Pharmaceutical is a South Korean top-5 pharmaceutical company developing innovative obesity, oncology, and rare disease drugs through proprietary platforms (LAPSCOVERY, PENTAMBODY, HARP AI). Revenue derives from global licensing deals, Korean prescription drug sales, and CDMO services.
Ownership category
akta.pro rank

Hanmi Pharmaceutical industry classification

Industry
Product category
Pharmaceutical Products
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Innovative pharmaceutical products
  • Long-acting biologics
  • Obesity drug development
  • Contract pharmaceutical manufacturing
  • Drug licensing partnerships

Where Hanmi Pharmaceutical is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices8 records

Markets served

Hanmi Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Licensing-out Deals: Hanmi licenses its proprietary drug candidates to global pharmaceutical companies for upfront payments, milestone payments, and royalties. Examples include $1.26B deal with Eli Lilly for sonefpeglutide ($75M upfront + $1.185B milestones), and deals with Sanofi, Janssen, Boehringer Ingelheim, MSD, and Genentech. Revenue recognition occurs at deal signing, milestone achievements, and ongoing royalties post-launch.
  2. CDMO Services: Contract development and manufacturing services across three divisions: Bio (biopharmaceuticals with microbial culture), Fine Chemical (APIs, peptides, PEG, NTP, mRNA cap analog), and Chemical (synthetic medicines with 6+ billion tablets annual capacity). Services include development, GMP manufacturing, and regulatory support.
  3. Pharmaceutical Product Sales: Direct sales of pharmaceutical products in Korea and through international subsidiaries. Products include Amosartan (antihypertensive), Amodipin, and other incrementally modified drugs. Korean market leadership with #1 outpatient prescription ranking for multiple years.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels5 records

Hanmi Pharmaceutical product offering

Product offering

Core offering

Hanmi Pharmaceutical develops, manufactures, and commercializes innovative pharmaceutical products across obesity/metabolism, oncology, and rare diseases using proprietary platform technologies (LAPSCOVERY, PENTAMBODY, HARP AI, IMD/New Formulation). The company sells branded drugs directly in Korea and China, licenses out proprietary drug candidates to global pharma partners (Eli Lilly, Sanofi, Janssen, MSD, Genentech), and provides CDMO services across Bio, Fine Chemical, and Chemical divisions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Amosartan World's first fixed-dose combination (FDC) of Amlodipine and Losartan for hypertension treatment, sold in Korea as a major breakthrough product in the cardiovascular therapeutic area.
  • Amodipin Korea's first incrementally modified drug (IMD) — a new salt form of amlodipine for hypertension treatment, patented in 2004 and commercially launched.
  • Rolontis (eflapegrastim) FDA-approved long-acting G-CSF biologic (eflapegrastim) developed using LAPSCOVERY platform for treatment of chemotherapy-induced neutropenia. Included in NCCN Treatment Guidelines for 32 cancer centers in the US.
  • Efpeglenatide (GLP-1 obesity and diabetes drug) Hanmi's proprietary GLP-1 receptor agonist for obesity and diabetes treatment. Korea's first independently developed obesity therapy, demonstrating best-in-class protective efficacy for cardiovascular/renal disease among GLP-1s. Licensed to Laboratorios Sanfer for exclusive distribution in Mexico.
  • Sonefpeglutide (LAPSGLP-2 analog) Long-acting GLP-2 analog developed using LAPSCOVERY platform for treatment of short bowel syndrome, currently in global Phase 2 trial. Licensed to Eli Lilly for $1.26 billion in upfront and milestones.
  • HM500197 (LA-MSTN) World's first peptide-based long-acting myostatin (LA-MSTN) inhibitor for obesity, designed to selectively inhibit myostatin and increase skeletal muscle-focused lean mass while minimizing off-target activity. Can be developed as combination therapy with GLP-1-based treatments.
  • Efocipegtrutide (LAPSTriple Agonist) Long-acting triple agonist (GLP-1/GIP/Glucagon) for treatment of obesity and MASH (non-alcoholic steatohepatitis), granted FDA Fast Track designation.
  • Efeglucagon / Efpegerglucagon (HM15136) Long-acting glucagon analog being developed as the world's first once-weekly formulation for congenital hyperinsulinism, a rare disease with no current FDA-approved treatment. Received FDA Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations.
  • CDMO Services Contract Development and Manufacturing Organization services across three divisions: Bio (biopharmaceuticals with microbial culture and biochemical reaction processes), Fine Chemical (APIs, peptides, PEG, NTP, mRNA cap analog), and Chemical (synthetic medicines with 6+ billion tablets annual capacity). Services include development, GMP manufacturing, and regulatory support.

Quantifiable outcome

  • 28.7% mean weight loss achieved by Eli Lilly's retatrutide setting benchmark for obesity drugs (source for market context)
  • +2 more outcomes

Companies that use Hanmi Pharmaceutical

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Hanmi Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Hanmi Pharmaceutical partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered flagship, core and minor.

  • Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 1 June 2026Licensing agreement worth up to $1.26 billion for sonefpeglutide (LAPSGLP-2 analog) for short bowel syndrome. Hanmi receives $75 million upfront and up to $1.185 billion in clinical development, regulatory, and commercialization milestone payments, plus royalties. Lilly gains exclusive worldwide rights outside Korea. Hanmi continues global Phase 2 trial while Lilly explores additional clinical trials.
  • OrganoncoreChannel Partner/ Reseller/ Distributor · 21 May 2026Supply agreement to export three combination medications for cardiovascular and respiratory health to Malaysia and Philippines. Hanmi supplies finished products while Organon handles marketing, distribution, and sales in local markets. Partnership targets rapidly growing Southeast Asian pharmaceutical market driven by increasing chronic disease prevalence.
  • Laboratorios SanfercoreChannel Partner/ Reseller/ Distributor · 11 February 2026Exclusive distribution agreement for efpeglenatide GLP-1 obesity drug and Dapalon-lineup diabetes treatments in Mexico. Hanmi supplies finished formulations while Sanfer handles regulatory approvals, marketing, and sales. Mexico has high obesity prevalence (36.86%) and diabetes prevalence (16.4%), making it strategically valuable market.
  • Aptose BiosciencesflagshipStrategic or Co-development Partner · 19 November 2025Hanmi acquiring all outstanding shares of Aptose at C$2.41 per share in cash (28% premium over 30-day VWAP). Hanmi already owns nearly 20% of Aptose and has provided debt support of over US$30 million during past 18 months. Deal supports continued development of tuspetinib-based therapy for AML. First direct entry into North America for Hanmi.
  • LegoChem BiosciencescoreStrategic or Co-development Partner · 1 January 2023Joint development of bsAb ADC (bispecific antibody-drug conjugate) for cancer using PENTAMBODY platform.
  • AffaMed TherapeuticsminorChannel Partner/ Reseller/ Distributor · 1 January 2021Licensing-out of Luminate (risuteganib) for dry AMD to Greater China region.
  • Aptose BiosciencescoreStrategic or Co-development Partner · 1 January 2021Licensing agreement for tuspetinib (HM43239, myeloid kinome inhibitor) for AML worldwide. Hanmi also providing financing support and pursuing acquisition of Aptose.
  • ArthrexminorChannel Partner/ Reseller/ Distributor · 1 January 2021Licensing-out of HA injection (sodium hyaluronate) for joint articular use in US.
  • MSD (Merck & Co.)coreStrategic or Co-development Partner · 1 January 2020Licensing agreement for efinopegdutide (HM12525A, GLP-1/Glucagon) for MASH worldwide excluding Korea.
  • GC BiopharmaminorStrategic or Co-development Partner · 1 January 2020Enzyme replacement therapy partnership for HM15421/GC1134A (long-acting ERT) for lysosomal storage disease.
  • Innovent BiologicscoreStrategic or Co-development Partner · 1 January 2017PENTAMBODY-based bispecific antibody BH2950/IBI315 (PD-1/HER2 antagonist) for cancer development.
  • Genentech (Roche)coreStrategic or Co-development Partner · 1 January 2016Licensing agreement for belvarafenib (HM95573, pan-RAFi) for solid tumor treatment.
  • SanoficoreStrategic or Co-development Partner · 1 January 2015Multiple licensing agreements including Amosartan Q for CIS markets and joint development of fixed-dose combinations like Robelito (ARB-statin combination), Korea's first such combination drug.
  • Janssen (Johnson & Johnson)coreStrategic or Co-development Partner · 1 January 2015Licensing agreement for HM12525A (GLP-1/Glucagon dual agonist) for diabetes and obesity worldwide excluding Korea, China, and Greater China.
  • Boehringer IngelheimminorStrategic or Co-development Partner · 1 January 2015Licensing partnership for autoimmune disease therapeutics.
  • Zai LabminorChannel Partner/ Reseller/ Distributor · 1 January 2015Licensing agreement for olmutinib (HM61713, EGFRi) for solid tumor in China.
  • Eli LillycoreStrategic or Co-development Partner · 1 January 2015Licensing agreement for poseltinib (HM71224, BTKi) for autoimmune diseases worldwide excluding Korea and Greater China.
  • LegoChem BiosciencescoreStrategic or Co-development Partner · 1 January 2015Joint development of dual antibody ADC anticancer drug using PENTAMBODY ConjuAll platform technology.
  • Spectrum Therapeutics (Assertio)coreStrategic or Co-development Partner · 1 January 2012Licensing agreement for poziotinib (HM781-36B, pan-HER inhibitor) for solid tumors worldwide excluding Korea and China. Strategic investment of KRW 24 billion in Spectrum.
  • SpectrumcoreStrategic or Co-development Partner · 1 January 2012Licensing agreement for Rolvedon (eflapegrastim, HM10460A, G-CSF) for neutropenia worldwide excluding Korea, China, and Japan.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Hanmi Pharmaceutical competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Novo Nordisk is the global GLP-1 obesity/diabetes market leader with semaglutide (Ozempic/Wegovy). Directly comparable as the dominant obesity/metabolism incumbent against whose commercial franchise Hanmi's efpeglenatide and other pipeline assets must compete for market share.
  • Eli Lilly and Company: Eli Lilly is the global leader in obesity therapeutics with retatrutide and tirzepatide franchises, and is also Hanmi's licensing partner for sonefpeglutide. Comparable as an obesity/metabolism market incumbent whose commercial scale sets the benchmark Hanmi's pipeline must compete against.

Direct peers

  • Celltrion: Celltrion is a leading Korean biopharmaceutical company specializing in biosimilars and novel biologics, with global licensing partnerships. Directly comparable to Hanmi's biologics manufacturing capabilities (Pyeongtaek Bioplant) and biosimilar/innovative biologics pipeline strategy.
  • Dong-A Pharmaceutical: Dong-A Pharmaceutical is a Korean pharmaceutical company of similar size with branded generics, specialty therapeutics, and incremental drug modification focus. Comparable to Hanmi's domestic prescription franchise, R&D pipeline, and Korean market leadership ambitions.
  • Yuhan Corporation: Yuhan Corporation is one of the largest Korean pharmaceutical companies by revenue, with a similar branded-pharma business model and growing CDMO operations. It is directly comparable to Hanmi in scale, therapeutic focus areas (respiratory, oncology, chronic disease), and Korean-market leadership profile.
  • Chong Kun Dang Pharmaceutical: Chong Kun Dang is a Korean pharmaceutical company with similar size, branded-generic portfolio, and incremental drug modification focus. Directly comparable to Hanmi's domestic Korean prescription business and IMD/new formulation technology platform.
  • Daewoong Pharmaceutical: Daewoong Pharmaceutical is a Korean top-tier pharmaceutical company with direct overlap in incrementally modified drugs, GLP-1 development (envafolimab), and botulinum toxin franchises. Similar in size, business model, and pipeline focus to Hanmi's branded pharma business.
  • Samsung Biologics: Samsung Biologics is a global CDMO and biosimilars developer operating large-scale mammalian cell culture manufacturing facilities. Comparable to Hanmi's CDMO business (Bio division) and global pharma contract manufacturing partnerships with Lilly, Roche, and other major companies.
  • LG Chem Life Sciences: LG Chem's Life Sciences division is a Korean specialty pharmaceutical company focused on innovative drugs, vaccines, and CDMO services. Comparable to Hanmi in branded pharma operations, specialty therapeutics focus, and CDMO scale.

Emerging players

  • Innovent Biologics: Innovent Biologics is a Chinese innovative biopharmaceutical company that partnered with Hanmi on PENTAMBODY-based bispecific antibody BH2950/IBI315. Comparable as an emerging oncology biologics developer with similar bispecific antibody technology focus and licensing partnership patterns.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Hanmi Pharmaceutical social profiles

Digital presence

Hanmi Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hanmi Pharmaceutical leadership team

Management profile

Number of profiles

Profiles9 records

Hanmi Pharmaceutical subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Hanmi Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hanmi Pharmaceutical M&A and investment

M&A and investment

M&A1 record

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hanmi Pharmaceutical

What does Hanmi Pharmaceutical do?

Hanmi Pharmaceutical develops, manufactures, and commercializes innovative pharmaceutical products across obesity/metabolism, oncology, and rare diseases using proprietary platform technologies (LAPSCOVERY, PENTAMBODY, HARP AI, IMD/New Formulation). The company sells branded drugs directly in Korea and China, licenses out proprietary drug candidates to global pharma partners (Eli Lilly, Sanofi, Janssen, MSD, Genentech), and provides CDMO services across Bio, Fine Chemical, and Chemical divisions.

Is Hanmi Pharmaceutical a public or private company?

Hanmi Pharmaceutical is a public company. It is classified as public and is currently operating.

When was Hanmi Pharmaceutical founded?

Hanmi Pharmaceutical was founded in 1973. It employs 51 to 100 people.

Where is Hanmi Pharmaceutical based?

Hanmi Pharmaceutical is headquartered in Seoul, South Korea, in the Asia region.

How does Hanmi Pharmaceutical make money?

Three revenue lines are on record. Licensing-out Deals are the primary driver. The others are CDMO Services and pharmaceutical Product Sales.

Who are Hanmi Pharmaceutical's main competitors?

Broad incumbents on record are Novo Nordisk and Eli Lilly and Company. Direct peers are Celltrion, Dong-A Pharmaceutical, Yuhan Corporation, Chong Kun Dang Pharmaceutical, Daewoong Pharmaceutical, Samsung Biologics and LG Chem Life Sciences. Innovent Biologics is listed as an emerging player.

Does Hanmi Pharmaceutical have an API?

No public API is recorded for Hanmi Pharmaceutical.

What industry is Hanmi Pharmaceutical in?

Hanmi Pharmaceutical's product category is Pharmaceutical Products. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Businesskorea53rd anniversary of Hanmi Group, the value of 'respect for humanity' practiced by 900 employees.Hanmi Group held its 53rd anniversary volunteer week from September to October, with over 900 employees participating in 13 programs across environment, health, sharing, and companionship. Participation nearly doubled from about 500 last year, and the group aims to expand its sharing culture sustainably.BusinesskoreaHanmi Drugs Show Promise in Phase 1 TrialsHanmi Pharmaceuticals reported Phase 1 trial results for two anticancer candidates, HM97662 and BH3120, at ESMO Congress 2026. HM97662 showed antitumor activity in ARID1A-mutant ovarian clear cell carcinoma and SMARCB1-loss chordoma, while BH3120 had reduced liver toxicity. The company plans to proceed to dose-expansion studies.The future of tradingHanmi Pharmaceutical Attends Korea Investment & Securities Corp DayHanmi Pharmaceutical will attend Korea Investment & Securities Corp Day on Nov. 17, 2026, in Yeouido, Seoul. In-person group meetings with domestic and international institutional investors will begin at 3 p.m., covering third-quarter results and key R&D pipeline programs, followed by a Q&A session.Naver2026 Obesity Treatment Breakthrough: Hanmi Pharmaceutical’s GLP-1 Drug Eppe and the Synergy of Digital Health ManagementHanmi Pharmaceutical's Eppe GLP-1 obesity drug received approval as South Korea's 45th domestic new drug, with Phase 3 trials showing average weight loss of 9.75% and a 27% reduction in major cardiovascular events. The company plans to pair Eppe with its eppiday digital platform and seek approval for a digital convergence drug by 2028.NaverWeight-loss drug battle shifts from one-time prescriptions to long-term loyaltyHanmi Pharmaceutical's Eppe drug has attracted 2,464 patients, with 34.5% having prior weight-loss prescriptions. Eli Lilly partnered with Hims & Hers to distribute Zepbound and Foundayo, while Novo Nordisk treats patients as consumers. The shift toward long-term loyalty mirrors a subscription business model.Endpoints NewsMerck unwraps biopsy data for MASH drug it got from South Korea's HanmiMerck reported that its dual GLP-1/glucagon agonist cleared a mid-stage trial in MASH, sharing biopsy data on the drug it licensed from South Korea's Hanmi. The company announced the results on Thursday.The future of tradingHanmi Pharmaceutical Joins Sangsangin Securities Non-Deal RoadshowHanmi Pharmaceutical will attend a Sangsangin Securities non-deal roadshow in Seoul on Nov. 3, 2026, with one-on-one meetings starting at 9:10 a.m. The company will discuss its third-quarter 2026 business performance, followed by a Q&A session.BusinesskoreaGC Green Cross and Hanmi Pharmaceutical, technology export of Fabry disease treatment drugGC Green Cross and Hanmi Pharmaceutical signed an exclusive license with BioMarin for their Fabry disease drug LA-GLA, a subcutaneous ERT candidate. The deal is worth $475 million, with an initial $70 million advance and up to $405 million in milestones. The companies plan to accelerate global clinical trials and lead Korean market approval.The future of tradingHanmi Science Subsidiary Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin in USD 237.5 Million DealHanmi Pharmaceutical, a Hanmi Science subsidiary, licensed a Fabry disease therapy to BioMarin for USD 237.5 million, including USD 35 million upfront and USD 202.5 million in milestones. BioMarin gets exclusive worldwide rights, while Hanmi and GC retain South Korea approval and commercialization. The long-acting enzyme replacement therapy is in Phase 1/2 trials.The future of tradingHanmi Pharmaceutical Signs Fabry Disease Drug Licensing Deal With BioMarin Worth Up to USD 237.5 MillionHanmi Pharmaceutical signed a licensing agreement with BioMarin for Fabry disease treatment LA-GLA, worth up to $237.5 million. The deal includes $35 million upfront, $202.5 million in milestone payments and royalties, with BioMarin receiving exclusive global rights. The drug is in Phase 1/2 clinical trials in South Korea and abroad.